Jiangsu Hengrui Pharmaceuticals Co. $600276.SS, recognized as China’s most valuable pharmaceutical company by market capitalization, recorded a remarkable performance during its recent Hong Kong listing. The company secured 9.9 billion Hong Kong dollars (HKD), equivalent to 1.3 billion US dollars (USD), through an initial public offering characterized by intense demand. Shares jumped by 25% on Friday, reaching HKD 55.15 and marking a robust start after the offering was priced at the high end of the marketed range.

Jiangsu Hengrui Pharmaceuticals Co. $600276.SS, a prominent Chinese drug developer specializing in oncology and cardiovascular innovations, executed its secondary listing in Hong Kong by setting the share price at the upper limit. The company raised 9.9 billion Hong Kong dollars (approximately USD 1.3 billion), a capital infusion underlining the significant appetite for high-quality Chinese healthcare assets on the Hong Kong Stock Exchange.

Jiangsu Hengrui Pharmaceuticals $600276.SS, a leading Chinese biopharmaceutical company, has officially announced its plans to raise up to US$1.27 billion through an initial public offering (IPO) on the Hong Kong Stock Exchange. This move marks one of the largest pharmaceutical IPOs in Asia in recent months and reflects the company’s strategy to increase its visibility among global investors.